Clinical Trials Browser

Peritoneal Neoplasms

NCT02758951 2026-03-24

CAIRO6

Phase 2/3 Active not recruiting

358 enrolled

GastrointestinalGynecologic

Hyperthermia, Colonic Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms

NCT03252938 2026-02-19

INSIGHT

Phase 1 Active not recruiting

83 enrolled

GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT04762953 2026-02-03

STOPGAP

Phase 2 Active not recruiting

40 enrolled

GastrointestinalGynecologic

Peritoneal Neoplasms, Stomach Neoplasms

NCT03348150 2025-07-17

PERISCOPEII

Phase 3 Active not recruiting

102 enrolled

GastrointestinalGynecologic

Peritoneal Neoplasms, Stomach Neoplasms

NCT02571725 2025-05-23

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Phase 1/2 Active not recruiting

50 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05623787 2025-03-20

DWI-HighRisk

Phase NA Active not recruiting

30 enrolled

GastrointestinalGynecologic

Appendiceal Neoplasms, Carcinoma, Peritoneal Neoplasms, Colorectal Neoplasms

NCT03172416 2024-05-29

PIPAC

Phase 1 Active not recruiting

21 enrolled

GastrointestinalGynecologic

Peritoneal Neoplasms, Stomach Neoplasms

NCT04000906 2024-05-24

Nab-PIPAC

Phase 1 Active not recruiting

18 enrolled

GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Pancreatic Neoplasms, Peritoneal Neoplasms

NCT02113384 2021-07-28

LARC-EX

Active not recruiting

231 enrolled

GastrointestinalGynecologic

Peritoneal Neoplasms, Rectal Neoplasms

Clinical Trials

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

CAIRO6

INSIGHT

STOPGAP

PERISCOPEII

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

DWI-HighRisk

PIPAC

Nab-PIPAC

LARC-EX